CMA POLICY

Cannabis for Medical Purposes

This Canadian Medical Association (CMA) policy recognizes the urgency of meeting the needs of those individuals suffering from a terminal illness or chronic disease for which conventional therapies have not been effective and for whom cannabidiol (CBD) and tetrahydrocannabinol (THC) may provide relief.

The CMA welcomes the regulation of cannabis for medical purposes and recognizes the need for appropriate clinical trials and regulations. The policy is based on the current evidence and the potential benefits and risks of cannabis for medical purposes.

The CMA supports the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis.
2. Advise governments to establish regulatory frameworks that recognize the medical use of cannabis.
3. Promote the development of evidence-based clinical guidelines for the treatment of conditions for which cannabis may be beneficial.
4. Support the establishment of scientific bodies to oversee the research and development of cannabis.
5. Encourage governments to establish frameworks for the safe and regulated production, distribution, and use of cannabis for medical purposes.

The CMA policy is based on the current evidence and the potential benefits and risks of cannabis for medical purposes.

CMA Policybase - Canadian Medical Association